يعرض 18,261 - 18,280 نتائج من 18,495 نتيجة بحث عن 'significant ((((((greater decrease) OR (greatest decrease))) OR (mean decrease))) OR (a decrease))', وقت الاستعلام: 0.68s تنقيح النتائج
  1. 18261

    SEAwise synthesis of predicted impacts of changes in habitat and spatial management measures suggested in SEAwise for online tool حسب Dimitris Damalas (15976639)

    منشور في 2025
    "…<p dir="ltr">The SEAwise project works to deliver a fully operational tool that will allow fishers, managers, and policy makers to easily apply Ecosystem Based Fisheries Management. …"
  2. 18262

    Data Sheet 1_Impact of SARS-CoV-2 vaccination and of seasonal variations on the innate immune inflammatory response.pdf حسب Hend Jarras (13138641)

    منشور في 2025
    "…</p>Results<p>Our results show that IL-8 production after stimulation decreased after vaccination. In addition, the IL-8 response was significantly different depending on the season when the visit occurred, for both COVID-19 vaccinated and unvaccinated individuals.…"
  3. 18263

    Table 2_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.docx حسب Xinmao Song (5124035)

    منشور في 2025
    "…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …"
  4. 18264

    Table 1_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.doc حسب Xinmao Song (5124035)

    منشور في 2025
    "…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …"
  5. 18265

    Cardiac function. حسب Gerald Yu Liao (20490394)

    منشور في 2024
    "…<p><b>A.</b> C57BL/6J mice did not show age-related changes in LVMI (tibia). …"
  6. 18266

    Image 1_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.jpeg حسب Xinmao Song (5124035)

    منشور في 2025
    "…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …"
  7. 18267

    ZIKV infection enriches the HLA Class I pathway in brain tumour cells. حسب Matt Sherwood (22530221)

    منشور في 2025
    "…Normalised enrichment score (NES) denotes the degree to which the enrichment increased (+) or decreased (-). GSEA analysis significance is defined by p ≤ 0.05 and FDR ≤ 0.25. …"
  8. 18268

    The expression of PAX7 and MYOD1 correlate with differential expression of diverse chemokines in HuMuSC. حسب Katharine Striedinger (15503387)

    منشور في 2025
    "…<p><b>(a)</b> Quantification of protein expression for PAX7+ and MYOD1 positive HuMuSC at day 0, 3 and 6 in vitro, showing an inverse correlation as progressively PAX7 expression decreases and MYOD1 expression increases in HuMuSC as they activate <i>in vitro</i>. …"
  9. 18269

    DataSheet1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.pdf حسب Seungchan An (6256061)

    منشور في 2024
    "…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …"
  10. 18270

    Table1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.xlsx حسب Seungchan An (6256061)

    منشور في 2024
    "…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …"
  11. 18271

    Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  12. 18272

    Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  13. 18273

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  14. 18274

    DataSheet1_Efferocytosis dysfunction in CXCL4-induced M4 macrophages: phenotypic insights in systemic sclerosis in vitro and in vivo.docx حسب Erwan Le Tallec (19834785)

    منشور في 2024
    "…Additionally, circulating levels of CXCL4, a novel SSc biomarker, correlate with more severe fibrotic manifestations of the disease. …"
  15. 18275

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  16. 18276

    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  17. 18277

    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  18. 18278

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  19. 18279

    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"
  20. 18280

    Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

    منشور في 2025
    "…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …"